Xencor XNCR

HealthcareMarket cap $2B1 connection

Xencor engineers antibodies with enhanced properties using its XmAb technology - longer half-lives, better tumor targeting, or bispecific (targeting two antigens simultaneously). Its technology is licensed to Alexion, Merck, and Novartis. Bispecific antibodies are one of oncology's most exciting new drug classes.

Explore Xencor on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

Johnson & JohnsonHealthcare · $380BJanssen collaboration on bispecific antibodies

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Xencor's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=XNCR" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Xencor on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.